Sign in
Enrolling by invitationNo phase

An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

Key facts

Who runs it
University of California, Los Angeles
Where
Los Angeles, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Status
Enrolling by invitation
People taking part
70 people, planned
Started
26 Sept 2019
Expected to end
Aug 2040
Type of study
Observational
Treatments tested
  • autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
Record updated
18 December 2025

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • A patient is eligible for enrollment in the study if all of the following criteria are met:
  • the patient has been treated with an autologous ex vivo gene therapy product based on the EFS-ADA LV, as part of the OTL-101 clinical development program
  • the patient displays persistent detectable gene marking, as determined by the Investigator
  • the patient or, if applicable, the patient's parent(s)/legal guardian(s), are able and willing to provide informed consent

Who cannot take part

  • There are no exclusion criteria for participation in this observational LTFU study

Where in United States

Also in 1 other country, 1 site

  • Mattel Children's Hospital UCLA/Ronald Reagan UCLA Medical CenterLos Angeles, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This observational long-term follow-up study is designed to collect safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA LV encoding for human adenosine deaminase (ADA) gene (EFS-ADA LV), as part of the OTL-101 clinical development program. No investigational medicinal product will be administered to these patients as part of the OTL-101-6 study.

Treatments tested

  • autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Observational Long-term Follow-up Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)
Publications
Record updated
18 December 2025